Banyere C-CAR031

C-CAR031 bụ ọgwụgwọ GPC3 nke na-elekwasị anya na chimeric antigen receptor T-Cell (CAR-T), nke a na-amụ maka ọgwụgwọ HCC.

E gosipụtara ọganihu nyocha nke C-CAR031 na ọrịa kansa hepatocellular (HCC) n'ọnụ na nzukọ kwa afọ nke American Society of Clinical Oncology (ASCO) nke emere na Chicago na 2024.

Usoro: Nnwale nke mbụ n'ime mmadụ, nke mepere emepe, na-eji usoro titration ngwa ngwa yana nhazi i3+3. Ndị GPC3+ dị elu HCC pts ndị dara ≥ 1 line systemic systemic natara otu iv infusion nke C-CAR031 mgbe ọkwa lymphodepletion gasịrị. Isi ihe ndị bụ isi bụ nchekwa na ndidi, ndị ọzọ gụnyere pharmacokinetics na arụmọrụ mbụ. E nyere akara ihe ọjọọ (AEs) site na CTCAE 5.0, e wee nyochaa cytokine release syndrome (CRS) / immunoeffector cell-associated neurotoxicity syndrome (ICANS) dịka ụkpụrụ ASTCT 2019 si dị. Onye nyocha nyochara azịza ebumnuche site na RECIST 1.1.

Nsonaazụ: Dịka ọ dị na Jenụwarị 5, 2024, ngụkọta nke mmadụ 24 natara ọgwụ C-CAR031 na ọkwa dose 4 (DLs). Ndị niile nwere BCLC stage C HCC, 83.3% (20/24) nwere metastasis extrahepatic. Ọnụọgụ etiti nke usoro ọgwụgwọ gara aga bụ 3.5 (oke 1-6), 23 (95.8%) ndị natara ICI (ihe mgbochi mgbochi ahụ ji alụso ọrịa ọgụ) na TKIs (ihe mgbochi tyrosine kinase). A na-enyocha ule niile maka nchekwa. Enweghị nsí na-egbochi dose na ICANS. A hụrụ CRS na 22 (91.7%) na naanị 1 (4.2%) ọkwa (G) 3 CRS. Ndị kacha ≥G3 AE bụ lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) na mmụba transaminase (16.7%). Otu pt (4.2%) nwere G4 myelosuppression na 1 pt (4.2%) nwere G3 interstitial pneumonitis na DL4 nke G3 CRS kpatara. AE niile nwere ike ịgbanwe. A tụlere 22 pts maka irè. A hụrụ mbelata etuto ahụ na 90.9% pts, ọ bụghị naanị na ọnya intrahepatic kamakwa na ndị na-anaghị ewepụ hepatic na mbelata etiti nke 44.0% (oke, 3.4%-94.4%). Ọnụego njikwa ọrịa ahụ bụ 90.9% yana ọnụego nzaghachi ebumnuche (ORR) bụ 50.0% maka pts nke DL niile. Na DL4, ORR bụ 57.1%.

Mmechi: Ọmụmụ ihe ahụ gosiri nchekwa dị mma nke ọma ma na-agba ume ka C-CAR031 na-alụso ọrịa kansa ọgụ n'ime ndị ọrịa HCC dị elu a na-agwọ nke ọma.

Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com

Ntụaka

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)